Karuna Therapeutics, Inc.

karunatx.com

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2023 10-K, filed Feb 22, 2024. Its latest SEC filing is a 15-12G from Mar 28, 2024.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Develops drug candidates for psychiatric and neurological conditions, including KarXT for schizophrenia and psychosis related to Alzheimer’s disease.

How Did They Make Money?

FY2023 revenue

Did Revenues Turn Into Profits?

No. It lost $433.7M in FY2023.

Operating income, FY2023

−75654% of revenue

▲ +71% (Loss) vs FY2022 (−$289.7M, −2723%)

Net income, FY2023

−66312% of revenue

▲ +57% (Loss) vs FY2022 (−$276.3M, −2598%)

Free cash flow, FY2023

−59437% of revenue

▲ +70% (Loss) vs FY2022 (−$228.9M, −2152%)

How Were They Changing?

Since the FY2023 annual report

Mar 18, 2024 Bristol Myers Squibb completed its acquisition of Karuna Karuna became a wholly owned subsidiary of Bristol-Myers Squibb and requested Nasdaq delisting of its shares.

An additional drug candidate The earlier report describes a pipeline centered on KarXT and other muscarinic-targeted candidates; the latest adds an exclusively licensed channel candidate intended for major depressive disorder.

Who Did They Compete With?

Competes with Otsuka Holdings, Lundbeck, Johnson & Johnson, Eli Lilly, Abbvie, HLS Therapeutics, Sumitomo Pharma, Intra-Cellular Therapies, Alkermes, Indivior, Bioxcel Therapetics, Luye Pharma, Teva Pharmaceuticals, Acadia Pharmaceuticals, Roche, Neurocrine Biosciences, SyneuRx, Newron Pharmaceuticals, MapLight Therapeutics, and Reviva Pharmaceuticals

Comments